In an effort to save costs and make its financial resources last longer, Recursion Pharmaceuticals (NASDAQ: RXRX) is slimming down and streamlining. After the biotech updated its strategy to do so on Tuesday, investors became more hopeful on its future, bidding the stock up; it closed 1.6% higher at the end of the day. This rise outpaced that of the S&P 500 (SNPINDEX: ^GSPC), which increased by 0.55%.
Job cuts coming, cash runway extended
Before market open, Recursion disclosed in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC) that it was taking a series of measures to streamline its operations.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Image source: Getty Images.
This will consist of a workforce reduction of around 20%, the company wrote. It anticipates booking around $11 million in charges related to this, in costs that include severance payments, benefit payouts, and other items, during the current year. This should comprise the bulk of the total charges incurred by this restructuring effort.
With this, its cash burn should end up at less than $450 million in 2025, and under $390 million in 2026. This could be alleviated by more than $100 million in milestone payments Recursion is eligible to be paid for hitting certain progress markers by the close of 2026.
The company added that it’s estimating the level of cash, cash equivalents, and restricted cash will land at over $500 million at the end of its current (second) quarter. This would be down, albeit not by much, from the $509 million at the conclusion of the first quarter.
Still, Recursion said that with the planned streamlining measures in place, its cash runway should last into the fourth quarter of 2027.
Time to talk the talk
While news of job cuts is never pleasant to hear, on the flip side, it’s encouraging that Recursion is making a push to extend its life as a business. The proof will be in the doing, of course, but for now, investors seem cautiously optimistic about the company’s strategy.
Should you invest $1,000 in Recursion Pharmaceuticals right now?
Before you buy stock in Recursion Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $660,341!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $874,192!*
Now, it’s worth noting Stock Advisor’s total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
